Trials / Completed
CompletedNCT01045369
A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects
A Phase IV 48 Week, Open Label, Pilot Study of Kaletra and Intelence Tablets in Naive Subjects
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Therapeutic Concepts · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if using a combination of other drug classes, like the ones that Kaletra® and Intelence™ belong to, can still help reduce the amount of HIV in your blood. Using Kaletra® and Intelence™ without other drugs is not approved by the FDA and so their use in this study is experimental.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Kaletra and Intelence Tablets | Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day. |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2011-04-01
- Completion
- 2011-06-01
- First posted
- 2010-01-11
- Last updated
- 2017-05-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01045369. Inclusion in this directory is not an endorsement.